The mainstreaming of psychedelic-assisted therapy raises complex questions about how to responsibly integrate these treatments into existing legal and medical systems. The authors argue that current regulatory frameworks, originally designed for conventional pharmaceuticals, may be ill-suited to the unique ethical, clinical, and cultural dimensions of psychedelic substances. They examine potential conflicts between medical oversight and the diverse traditions from which these therapies emerge, and suggest that careful, inclusive policy development is needed to balance innovation with patient safety and respect for indigenous knowledge. The piece highlights the importance of anticipating regulatory challenges before widespread clinical adoption occurs.
Touch in psychotherapy remains controversial, but its role is gaining new attention with the return of psychedelic-assisted therapy, where altered states of consciousness may make touch particularly relevant. The text discusses the historical debate and current considerations around therapeutic touch, suggesting that its integration into psychedelic-assisted therapy warrants careful examination given the unique vulnerabilities and therapeutic opportunities presented by altered states.
Medical exceptionalism—treating psychedelics primarily as medical interventions—is only one of many possible frameworks for their use, understanding, and regulation. Cohen and Marks argue that this narrow medical lens can overlook alternative approaches rooted in community, ritual, or personal growth. The authors suggest that a broader perspective could lead to more equitable and culturally appropriate access pathways.